Inmagene Biopharmaceuticals picks up $21m Series B

Inmagene Biopharmaceuticals, a Chinese drug developer, has secured $21 million in Series B financing.

Inmagene Biopharmaceuticals, a Chinese drug developer, has secured $21 million in Series B financing. The investors included Vertex Ventures China, Panacea Venture, Kunlun Capital and SCVC.

Source: Press Release